UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED
PURSUANT
TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS
THERETO FILED
PURSUANT TO § 240.13d-2
(Amendment No. 2)*
| MoonLake
Immunotherapeutics |
| (Name of Issuer) |
| |
| Class A ordinary share, par value $0.0001 per share |
| (Title of Class of Securities) |
| |
| G4444C102 |
| (CUSIP Number) |
| |
| 31 December 2023 |
| (Date of Event Which Requires Filing of the Statement) |
Check the appropriate box to designate the rule
pursuant to which this Schedule is filed:
o Rule
13d-1(b)
x Rule
13d-1(c)
o Rule
13d-1(d)
The remainder of this cover page shall be filled
out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this
cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
| Cusip No. G4444C102 |
13G |
Page 2 of 7 Pages |
| 1. |
NAME OF REPORTING PERSONS
Merck Healthcare KGaA, Darmstadt Germany an affiliate of Merck KGaA,
Darmstadt, Germany
|
| 2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) o
(b) o |
| 3. |
SEC USE ONLY
|
| 4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Germany
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
5.
|
SOLE VOTING POWER
2,787,5091
|
|
6.
|
SHARED VOTING POWER
0
|
|
7.
|
SOLE DISPOSITIVE POWER
2,787,5091
|
|
8.
|
SHARED DISPOSITIVE POWER
0
|
| 9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,787,5091
|
| 10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS)
o |
| 11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.7%2
|
| 12. |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
|
1
The record holder of the securities covered by this Schedule 13G is
Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA Darmstadt, Germany. Merck Healthcare KGaA, Darmstadt Germany is a
dominantly controlled subsidiary of Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is
a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of Merck Healthcare KGaA, Darmstadt Germany. Merck KGaA,
Darmstadt Germany is dominantly controlled by E.Merck KG, Darmstadt Germany. Merck Healthcare KGaA, Darmstadt Germany, currently holds
2,787,509 Class A ordinary shares of the Issuer.
2
This percentage is based upon 59,940,529 Class A ordinary shares outstanding
as of November 01 2023 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on November 14, 2022.
| Cusip No. G4444C102 |
13G |
Page 3 of 7 Pages |
| 1. |
NAME OF REPORTING PERSONS
Merck KGaA, Darmstadt, Germany
|
| 2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) o
(b) o |
| 3. |
SEC USE ONLY
|
| 4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Germany
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
5.
|
SOLE VOTING POWER
2,787,5093
|
|
6.
|
SHARED VOTING POWER
0
|
|
7.
|
SOLE DISPOSITIVE POWER
2,787,5093
|
|
8.
|
SHARED DISPOSITIVE POWER
0
|
| 9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,787,5093
|
| 10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS)
o |
| 11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.7%4
|
| 12. |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
|
3
The record holder of the securities covered by this Schedule 13G is
Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA Darmstadt, Germany. Merck Healthcare KGaA, Darmstadt Germany is a
dominantly controlled subsidiary of Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is
a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of Merck Healthcare KGaA, Darmstadt Germany. Merck KGaA,
Darmstadt Germany is dominantly controlled by E.Merck KG, Darmstadt Germany. Merck Healthcare KGaA, Darmstadt Germany, currently holds
2,787,509 Class A ordinary shares of the Issuer.
4
This percentage is based upon 59,940,529 Class A ordinary shares outstanding
as of November 01 2023 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on November 14, 2022.
| Cusip No. G4444C102 |
13G |
Page 4 of 7 Pages |
| 1. |
NAME OF REPORTING PERSONS
E.Merck KG, Darmstadt Germany
|
| 2. |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) o
(b) o |
| 3. |
SEC USE ONLY
|
| 4. |
CITIZENSHIP OR PLACE OF ORGANIZATION
Germany
|
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH |
5.
|
SOLE VOTING POWER
2,787,5095
|
|
6.
|
SHARED VOTING POWER
0
|
|
7.
|
SOLE DISPOSITIVE POWER
2,787,5095
|
|
8.
|
SHARED DISPOSITIVE POWER
0
|
| 9. |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,787,5095
|
| 10. |
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE
INSTRUCTIONS)
o |
| 11. |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.7%6
|
| 12. |
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
|
5
The record holder of the securities covered by this Schedule 13G is
Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA Darmstadt, Germany. Merck Healthcare KGaA, Darmstadt Germany is a
dominantly controlled subsidiary of Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt Germany. Merck KGaA, Darmstadt, Germany is
a publicly traded company (Frankfurt Stock Exchange, DAX 40) and the beneficiary of Merck Healthcare KGaA, Darmstadt Germany. Merck KGaA,
Darmstadt Germany is dominantly controlled by E.Merck KG, Darmstadt Germany. Merck Healthcare KGaA, Darmstadt Germany, currently holds
2,787,509 Class A ordinary shares of the Issuer.
6
This percentage is based upon 59,940,529 Class A ordinary shares outstanding
as of November 01 2023 as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission
on November 14, 2022.
| Cusip No. G4444C102 |
13G |
Page 5 of 7 Pages |
| Item 1(a). |
Name of Issuer: |
| |
|
| |
MoonLake Immunotherapeutics |
| |
|
| Item 1(b). |
Address of Issuer’s Principal Executive Offices: |
| |
|
| |
Dorfstrasse 29 |
| |
Zug, Switzerland 6300 |
| |
|
| Item 2(a). |
Name of Person Filing: |
| |
|
| |
This Schedule 13G is being filed by each of the following persons (each,
a “Reporting Person” and together, the “Reporting Persons”):
Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA
Darmstadt Germany
Merck KGaA, Darmstadt, Germany
E.Merck KG, Darmstadt, Germany
The Reporting Persons have entered into a Joint Filing Agreement, a
copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which the Reporting Persons have agreed to file this Schedule
13G jointly in accordance with the provisions of Rule 13d-1(k)(l) of the Securities Exchange Act of 1934, as amended. |
| |
|
| Item 2(b). |
Address of Principal Business Office or, if none, Residence: |
| |
|
| |
Merck Healthcare KGaA, Darmstadt, Germany an affiliate of Merck KGaA
Darmstadt, Germany, and Merck KGaA: Frankfurter Strasse 250, 64293 Darmstadt, Germany
E.Merck KG: Emanuel-Merck-Platz 1, 64293 Darmstadt, Germany |
| |
|
| Item 2(c). |
Citizenship: |
| |
|
| |
The Reporting Persons Merck Healthcare KGaA an affiliate of Merck KGaA Darmstadt Germany, Merck KGaA and E.Merck KG are organized in Germany. |
| |
|
| Item 2(d). |
Title of Class of Securities: |
| |
|
| |
Class A ordinary shares, par value $ 0.0001 per share |
| |
|
| Item 2(e). |
CUSIP Number: |
| |
|
| |
G4444C102 |
| |
|
| Item 3. |
If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: |
| |
Not applicable |
| |
(a) |
o |
Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); |
| |
(b) |
o |
Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); |
| |
(c) |
o |
Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); |
| |
(d) |
o |
Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
| |
(e) |
o |
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); |
| |
(f) |
o |
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); |
| |
(g) |
o |
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); |
| |
(h) |
o |
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| |
(i) |
o |
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); |
| |
(j) |
o |
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); |
| |
(k) |
o |
Group, in accordance with § 240.13d-1(b)(1)(ii)(K). |
| Cusip No. G4444C102 |
13G |
Page 6 of 7 Pages |
| Item 4. |
Ownership: |
| |
|
| |
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
| |
(a) |
Amount beneficially owned: Each of the Reporting Persons may be deemed to beneficially own 2,787,509 Class A ordinary shares. See notes 1, 3 and 5 on the Cover Pages, which are incorporated herein. |
| |
|
|
| |
(b) |
Percent of class: 4.7%; see notes 2, 4 and 6 on the Cover Pages, which are incorporated herein. |
| |
|
|
| |
(c) |
Number of shares as to which the Reporting Persons have: |
| |
|
(i) |
Sole power to vote or to direct the vote: 2,787,509 |
| |
|
(ii) |
Shared power to vote or to direct the vote: 0 |
| |
|
(iii) |
Sole power to dispose or to direct the disposition of: 2,787,509 |
| |
|
(iv) |
Shared power to dispose or to direct the disposition of: 0 |
| Item 5. |
Ownership of Five Percent or Less of a Class: |
| |
|
| |
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x. |
| |
|
| Item 6. |
Ownership of More Than Five Percent on Behalf of Another Person: |
| |
|
| |
Not applicable |
| |
|
| Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: |
| |
|
| |
Not applicable |
| |
|
| Item 8. |
Identification and Classification of Members of the Group: |
| |
|
| |
Not applicable |
| |
|
| Item 9. |
Notice of Dissolution of Group: |
| |
|
| |
Not applicable |
| |
|
| Item 10. |
Certifications: |
| |
|
| |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
| Cusip No. G4444C102 |
13G |
Page 7 of 7 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and correct.
| MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY an affiliate of Merck KGaA, Darmstadt, Germany |
|
MERCK HEALTHCARE KGAA, DARMSTADT, GERMANY an affiliate of Merck KGaA, Darmstadt, Germany |
| Date: |
February 14, 2024 |
|
Date: |
February 14, 2024 |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| By: |
/s/ Matthias Muellenbeck |
|
By: |
/s/ Jens Eckhardt |
| |
|
|
|
|
| Name: |
Matthias Muellenbeck |
|
Name: |
Jens Eckhardt |
| |
|
|
|
|
| Title: |
SVP Business Development and Alliance Management |
|
Title: |
Head of Legal Business Development |
| MERCK KGAA, DARMSTADT, GERMANY |
|
MERCK KGAA, DARMSTADT, GERMANY |
| |
|
|
|
|
| Date: |
February 14, 2024 |
|
Date: |
February 14, 2024 |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| By: |
/s/ Jens Eckhardt |
|
By: |
/s/ Johannes Eckhardt |
| |
|
|
|
|
| Name: |
Jens Eckhardt |
|
Name: |
Johannes Eckhardt |
| |
|
|
|
|
| Title: |
Head of Legal Business Development |
|
Title: |
Head of Legal – M&A, Ventures & Finance |
| E.MERCK KG, DARMSTADT, GERMANY |
|
E.MERCK KG, DARMSTADT, GERMANY |
| |
|
|
|
|
| Date: |
February 14, 2024 |
|
Date: |
February 14, 2024 |
| |
|
|
|
|
| |
|
|
|
|
| |
|
|
|
|
| By: |
/s/ Johannes Eckhardt |
|
By: |
/s/ Kristin Eibisch |
| |
|
|
|
|
| Name: |
Johannes Eckhardt |
|
Name: |
Kristin Eibisch |
| |
|
|
|
|
| Title: |
Attorney-in-Fact |
|
Title: |
Attorney-in-Fact |
| Cusip No. G4444C102 |
13G |
Exhibits |
EXHIBIT INDEX
Exhibit 99.1 Joint Filing Agreement, dated August 01, 2022, by and between Merck Healthcare KGaA an affiliate of Merck KGaA, Darmstadt, Germany, Merck KGaA, Darmstadt, Germany and E.Merck KG, Darmstadt, Germany.
Exhibit 99.2 Power of Attorney
Exhibit 99.1
JOINT
FILING AGREEMENT
Pursuant to Rule 13d-1(k)(1)
of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the
Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of MoonLake Immunotherapeutics.
This Joint Filing Agreement
may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.
Dated:
Darmstadt, August 01, 2022
| MERCK HEALTHCARE KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany |
|
MERCK HEALTHCARE KGaA, Darmstadt Germany an affiliate of Merck KGaA, Darmstadt, Germany |
| |
|
|
| By: |
/s/ Matthias Muellenbeck |
|
By: |
/s/ Jens Eckhardt |
| |
|
|
|
|
| Name: |
Matthias Muellenbeck |
|
Name: |
Jens Eckhardt |
| |
|
|
|
|
| Title: |
SVP Business Development & Alliance Management |
|
Title: |
Head of Legal Business Development |
| MERCK KGAA, DARMSTADT, GERMANY |
|
MERCK KGAA, DARMSTADT, GERMANY |
| |
|
|
|
|
| By: |
/s/ Jens Eckhardt |
|
By: |
/s/ Johannes Eckhardt |
| |
|
|
|
|
| Name: |
Jens Eckhardt |
|
Name: |
Johannes Eckhardt |
| |
|
|
|
|
| Title: |
Head of Legal Business Development |
|
Title: |
Senior Corporate Counsel |
| E.MERCK KG, DARMSTADT, GERMANY |
|
E.MERCK KG, DARMSTADT, GERMANY |
| |
|
|
|
|
| By: |
/s/ Johannes Eckhardt |
|
By: |
/s/ Kristin Eibisch |
| |
|
|
|
|
| Name: |
Johannes Eckhardt |
|
Name: |
Kristin Eibisch |
| |
|
|
|
|
| Title: |
Attorney-in-Fact |
|
Title: |
Attorney-in-Fact |
Exhibit 99.2
POWER OF ATTORNEY
E. Merck KG, Darmstadt, Germany (the “Company”),
hereby makes, constitutes and appoints each of Dr. Matthias Mülllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt,
or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact
(each of such persons and their substitutes being referred to herein as the “Attorney-in-Fact”), with full power to act for
the Company and in the Company’s name, place and stead, to: (i) sign any and all instruments, certificates and documents that
may be necessary, desirable or appropriate to be executed on behalf of E. Merck KG, Darmstadt, Germany, pursuant to Section 13 or
16 of the Securities Exchange Act of 1934, as amended, and any and all regulations promulgated thereunder, (ii) file the same (including
any amendments thereto), with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange
Commission and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such
Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the Company, it being understood that the documents
executed by such Attorney-in-Fact on behalf of the Company pursuant to this power of attorney shall be in such form and shall contain
such terms and conditions as such Attorney-in-Fact may approve in such Attorney-in-Fact’s discretion, granting unto said Attorney-in-Fact
full power and authority to do and perform each and every act and thing necessary, desirable or appropriate.
The Company hereby grants to the Attorney-in-Fact
full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise
of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally
present with full power of substitution or revocation, hereby ratifying and confirming all that such Attorney-in-Fact or such Attorney-in-Fact’s
substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein
granted.
This Power of Attorney shall remain in full force
and effect until January 31, 2023 unless earlier revoked by the Company in a signed writing delivered to the Attorney-in-Fact, or,
in respect of any Attorney-in-Fact named herein, until such person ceases to be an employee of Merck KGaA or one of its affiliates.
IN WITNESS WHEREOF, the undersigned have executed
this Power of Attorney as of April 19, 2022.
| |
E. Merck KG |
| |
|
| |
/s/ Dr. Frank Stangenberg-Haverkamp |
| |
Name: Dr. Frank Stangenberg-Haverkamp |
| |
Title: General Partner |
| |
|
| |
/s/ Johannes Baillou |
| |
Name: Johannes Baillou |
| |
Title: General Partner |
POWER OF ATTORNEY
E. Merck KG, Darmstadt, Germany
(the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Müllenbeck, MBA, Jens Eckhardt, Kristin
Eibisch, Steffen Siegler and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution,
the Company’s true and lawful attorney-in-fact (each of such persons and their substitutes being referred to herein as the “Attorney-in-Fact”),
with full power to act for the Company and in the Company’s name, place and stead, to: (i) sign any and all instruments, certificates
and documents that may be necessary, desirable or appropriate to be executed on behalf of E. Merck KG, Darmstadt, Germany, pursuant to
Section 13 or 16 of the Securities Exchange Act of 1934, as amended, and any and all regulations promulgated thereunder, (ii) file the
same (including any amendments thereto), with all exhibits thereto, and any other documents in connection therewith, with the Securities
and Exchange Commission and (iii) take any other action of any type whatsoever in connection with the foregoing which, in the opinion
of such Attorney-in-Fact, may be of benefit to, in the best interest of, or legally required by, the Company, it being understood that
the documents executed by such Attorney-in-Fact on behalf of the Company pursuant to this power of attorney shall be in such form and
shall contain such terms and conditions as such Attorney-in-Fact may approve in such Attorney-in-Fact’s discretion, granting unto
said Attorney-in-Fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate.
The Company hereby grants
to the Attorney-in-Fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper
to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might
or could do if personally present with full power of substitution or revocation, hereby ratifying and confirming all that such Attorney-in-Fact
or such Attorney-in-Fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney
and the rights and powers herein granted.
This Power of Attorney shall
remain in full force and effect until January 31, 2025 unless earlier revoked by the Company in a signed writing delivered to the Attorney-in-Fact,
or, in respect of any Attorney-in-Fact named herein, until such person ceases to be an employee of Merck KGaA or one of its affiliates.
IN WITNESS WHEREOF, the undersigned
have executed this Power of Attorney as of February 14, 2024.
| |
E. Merck KG |
| |
|
| |
/s/ Johannes Baillou |
| |
Name: Johannes Baillou |
| |
Title: General Partner |
| |
|
| |
/s/ Dr. Wolfgang Büchele |
| |
Name: Dr. Wolfgang Büchele |
| |
Title: General Partner |
Grafico Azioni MoonLake Immunotherapeut... (NASDAQ:MLTX)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni MoonLake Immunotherapeut... (NASDAQ:MLTX)
Storico
Da Dic 2023 a Dic 2024
